Hyderabad, India, May 16, 2018- Vivimed Labs Spain S.L, the parent of UQUIFA S.A, has signed definitive agreements to facilitate the acquisition of SONEAS, a Budapest (Hungary) head quartered CDMO company, focussed on the Inriovator Pharmaceutical and Fine Chemical sectors. The business has been acquired from Lochlomond and Euroventures which are both based out of Hungary.SONEAS has for the year 2017, reported revenues of €12.2mn.
The acquisition broadens UQUIFA’s market offering in the CDMO space by enhancing its ability to now undertake preclinical, phase I, 11 and III NCE project development. These projects can then also potentially feed into UQUIFA’s existing cGMP inspected and approved manufacturing facilities in Spain and Mexico, creating a high-value project pipeline.
In terms of technology, SONEAS brings a high level of competency in NCE development as well as new technologies such as metal catalysis and heterocyclic chemistry to the UQU IFA technology tool box. From a manufacturing perspective, SONEAS brings both cGMP pilot plant and over 180KL of key starting material (KSM) cGMP capacities to the UQUIFA portfolio. It also counts within its pipeline three customer projects which are in Phase 2a/2b and one in Phase 3 of the NCE development lifecycle.
UQUIFA believes the acquisition of SONEAS will allow it to expand faster into the CDMO sector (40% of UQUIFA sales) where it already hasan important presence inthe.geographles of USA,Europeand Japan. To build on the cost-effective development capabilities with aggressive timellnes and, to deliver effective results for the combined customer base, will be a key objective for UQUIFA, according to Mr Saurabh Gurnurkar, the Executive Director.
UQUIFA, has three US FDA inspected manufacturing sites across Spain and Mexico and, caters to the Generic API and CDMO API segments of the global pharmaceutical market. It has customer relationships with leading innovator and generic formulation companies and, has been a trusted franchise across regulated markets, for 80 years of its existence. Gilead Lifesciences, GSK, Mylan, Esteve Quimica, Apotex, Medinsa, and Actavis are some of the key customers of UQUIFA.
UQUIFA is the API business of Vivimed Labs Limited, a Pharmaceuticals and Specialty Chemicals company headquartered in Hyderabad, India. It has recently raised capital from OrbiMed, which is a leading healthcare investment firm, with over $14 billion in assets under management. For further information on UQU IFA, visit www.uquifa.com
About SONEAS :
SONEAS, established in 1996, with a team strength of 144 people,isa Budapest,Hungary headquartered firm with business verticals focused onR+D and ~MO, targeted at the Innovator Pharma and Fine Chemical.sectors.
In R+D, it is a professional chemical service provider with research and analytical labs across two operating sites in Budapest. It also has an 8,000 sq mtr facility which houses process R+D, kilo lab arid a cGM P approved pilot plant facility which was commissioned in 20Q2. In CMO,it is 0perating on
For further information on SONEAS, visit www.soneas.com